MOD-GRF 1-29 + Ipamorelin Stack

From Pepperpedia, the free peptide encyclopedia
MOD-GRF 1-29 + Ipamorelin Stack
Properties
CategoryStacks
Also known asMod-GRF Ipa, GRF Ipamorelin
Last updated2026-04-14
Reading time2 min read
Tags
stackgrowth-hormoneghrhghrp

Overview

The MOD-GRF 1-29 + Ipamorelin Stack is functionally equivalent in research design to the CJC-1295 (no DAC) + Ipamorelin Stack. MOD-GRF 1-29 is the same molecule as CJC-1295 without DAC — a tetrasubstituted GHRH(1-29) analog with enhanced peptide-bond stability but a half-life still measured in tens of minutes.

The "MOD-GRF" naming convention is more common in research-supply circles, while "CJC-1295 (no DAC)" is more common in clinical and pharmacology literature. Both refer to the same peptide and serve the same purpose: provide a short, physiologically pulsatile GHRH signal that pairs with Ipamorelin's ghrelin agonism.

Compounds in This Stack

Rationale

MOD-GRF 1-29 binds the GHRH receptor and primes somatotrophs for growth hormone release. Ipamorelin binds the ghrelin receptor and suppresses somatostatin, the brake on GH secretion. The combined signal produces a sharper, larger GH pulse than either compound alone.

This stack is preferred over the DAC variant when the research goal is preservation of pulsatile architecture. Continuous GHRH receptor occupancy, as occurs with DAC, may attenuate the natural pulsatile pattern of GH secretion that some downstream effects depend on.

Research Context

ComponentReceptorHalf-life
MOD-GRF 1-29GHRH receptor~30 minutes
IpamorelinGhrelin receptor~2 hours

Both compounds have well-characterized pharmacology in animal models and limited but consistent human data.

Typical Research Parameters

The stack is generally studied with two to three administrations per day, with the canonical timing being pre-bedtime, post-workout (in exercise-related research models), and an additional morning administration. Meals — particularly carbohydrate intake — within an hour of administration typically blunt measurable GH pulse amplitude.

Considerations

Researchers note that pulsatile fidelity depends on intermittent receptor engagement; sustained receptor occupancy is associated with somatotroph desensitization. This stack is therefore preferred for research designs prioritizing physiological signaling. The combination is research-only and not a clinical GH replacement protocol.

Related entries

  • IpamorelinA selective growth hormone secretagogue pentapeptide that stimulates GH release from the pituitary with minimal effects on cortisol, prolactin, and appetite compared to other GHRPs.
  • Mod GRF 1-29A modified 29-amino-acid fragment of growth hormone-releasing hormone (GHRH) with four amino acid substitutions for improved metabolic stability, commonly paired with GH-releasing peptides to stimulate pulsatile growth hormone secretion.